Takeda's zasocitinib Phase 3 studies for psoriasis show promising results, surpassing Amgen's drug in efficacy.

Takeda Pharmaceutical Co., Ltd (NYSE: TAK) disclosed positive top-line outcomes from two pivotal Phase 3 trials of zasocitinib (TAK-279) targeted at treating moderate-to-severe plaque psoriasis. The results showcased zasocitinib's superiority over placebo for primary goals - static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75 at week 16. The PASI 75 response rate significantly exceeded placebo starting as soon as week 4 and continued to rise through week 24. In addition, the trials successfully achieved all 44 ranked secondary goals, including PASI 90, PASI 100, and sPGA 0 compared to placebo and Amgen Inc.'s (NASDAQ: AMGN) Otezla (apremilast). This highlights the potential of a once-daily pill to offer complete skin clearance for Psoriasis patients. The findings suggest promising outcomes for zasocitinib.